Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials
Ed Gane(University of Auckland), Man‐Fung Yuen(University of Hong Kong - Shenzhen Hospital), Florian A. Lempp(Vir Biotechnology (Switzerland)), Andrea L. Cathcart(VIR Biotechnology (United States)), Anna I. Bakardjiev(VIR Biotechnology (United States)), Phillip S. Pang(Gilead Sciences (United States)), Vasant Jadhav(Alnylam Pharmaceuticals (United States)), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Gregory Hinkle(Alnylam Pharmaceuticals (United States)), Yesseinia Angleró-Rodríguez(Alnylam Pharmaceuticals (United States)), Patrick Haslett, Ling Shen(VIR Biotechnology (United States)), Jae Bum Kim(Lehigh University), Charalambos Kaittanis(Takeda (Japan)), Jörg Täubel(British Heart Foundation), Christy M. Hebner(VIR Biotechnology (United States)), Young‐Suk Lim(Asan Medical Center), Daniel Cloutier(VIR Biotechnology (United States)), Stuart Milstein(Alnylam Pharmaceuticals (United States)), Stephen A. Huang(Brigham and Women's Hospital), Maja M. Janas(Alnylam Pharmaceuticals (United States))
Cited by 102
Related Papers
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders
|Frontiers in Endocrinology|2016|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States
|Diabetes|2006|1.1k
Therapeutic siRNA silencing in inflammatory monocytes in mice
|Nature Biotechnology|2011|837